Obinutuzumab – Medxy AI

Chemotherapy-Free Frontline Therapy in Indolent B-Cell Non-Hodgkin Lymphoma: Insights from Mosunetuzumab and Response-Adapted Polatuzumab Vedotin with Obinutuzumab

By MedXY 08/17/2026

A novel chemotherapy-free regimen combining mosunetuzumab with response-adapted polatuzumab vedotin and obinutuzumab shows high complete response rates and durable progression-free survival in untreated indolent B-cell NHL with favorable safety.

Nephrology news Rheumatology

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

By MedXY 10/24/2025

The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis management.

Clinical Updates Hematology-Oncology news Specialties

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma

By MedXY 08/30/2025

This phase 2 study demonstrates that obinutuzumab plus lenalidomide achieves high response rates with durable progression-free survival and manageable toxicities in untreated high tumor burden follicular lymphoma, suggesting a promising frontline option.